Price
¥44,000
Availability (in Japan)
10 or more
(In Japan at 17:00,
Jan 22, 2025 in JST)
Size
1 mL (50 tests)
Clonality | Monoclonal | Clone | KOR-SA3544 | ||
---|---|---|---|---|---|
Isotype (Immunized Animal) | Mouse IgG1 | ||||
Applications |
|
||||
Immunogen (Antigen) | cell line (KOCL-22) established from bone marrow blood of patient with congenital leukemia | ||||
Reactivity [Gene ID] | Human[4680] |
||||
Storage buffer | PBS/1% BSA/0.09% NaN3 | ||||
Storage temp. | 冷蔵 | Conjugate | PE | Manufacturer | MBL |
Alternative names | CEACAM6, NCA, CEAL | ||||
Background | This monoclonal antibody (clone KOR-SA3544) was reactive with a surface antigen expressed on Philadelphia chromosome (Ph1)-positive acute lymphoblastic leukemia (ALL) without exception (26/26 cases). The recognized antigen is a nonspecific cross-reacting antigen (NCA)-50/90 (CD66c), one of the carcinoembryonic antigen (CEA)-related glycoproteins encoded by a member of the CEA gene family. The Philadelphia chromosome (Ph1) has been implicated as the causative factor in greater than 90% of chronic myelogenous leukemia (CML), in 25-30% of adult and 2-10% of childhood acute lymphoblastic leukemia (ALL) and in rare cases of acute myelogenous leukemia (AML). The presence of the Ph in leukemic cells of ALL patients usually indicates poor prognosis and high risk. Sequential monitoring of the Ph in ALL correlates with the activity of malignant clones and predicts impending clinical relapse, and therefore is useful in guiding clinical therapeutic decisions. |
||||
Related products | D028-3 Anti-CD66c (KOR-SA3544) (Human) mAb D028-4 Anti-CD66c (KOR-SA3544) (Human) mAb-FITC |
||||
Product category |
|